GSK Steps Up Parkinson’s Focus With US Biotech Deal - MSN
(Bloomberg) -- GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug development for Parkinson’s disease. GSK will pay $80 ...
Vesalius Announces Multi-Target Strategic Alliance with GSK to …
2 days ago · Central to our alliance with GSK is our shared conviction that targeting the causal factors of common diseases like Parkinson's disease is the key to developing breakthrough medicines faster and ...
GSK pays Flagship biotech $80M for preclinical neuro pact
2 days ago · GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that includes a preclinical small molecule initially targeting Parkinson’s disease.
Vesalius Announces Multi-Target Strategic Alliance with GSK
2 days ago · Vesalius Will Apply its Proprietary Platform to Identify Novel Intervention Points that GSK may Advance for the Treatment of Patients with Parkinson’s Disease GSK has Licensed a Preclinical Small Molecule Inhibitor Program CAMBRIDGE, Mass., Nov. 12, 2024 /PRNewswire/ -- Vesalius Therapeutics, a ...
GSK partners with Flagship startup to hunt for Parkinson’s drugs
2 days ago · Permission granted by Flagship Pioneering. Flagship Pioneering startup Vesalius Therapeutics has signed a deal with GSK, the companies announced Tuesday, for the British pharma to use its technology to find medicines for neurodegenerative disorders. Under the terms of the deal, GSK will hand Vesalius $80 million in upfront and equity payments.
GSK Steps Up Parkinson’s Focus With US Biotech Deal - Bloomberg Law News
2 days ago · GSK is looking to increase its drug pipeline for the future. GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug development for Parkinson’s disease. GSK will pay $80 million upfront and as much as $570 million to gain full development and commercialization rights to ...
Vesalius Announces Multi-Target Strategic… | Flagship Pioneering
2 days ago · Cambridge, Mass., November 12, 2024 – Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, today announced a multi-target strategic alliance with GSK to discover and develop novel treatments for Parkinson’s disease, and another undisclosed neurodegenerative indication.
Vesalius-GSK $650M pact: Targeting Parkinson’s root causes
1 day ago · More than two years since emerging from stealth, Vesalius Therapeutics Inc. signed its first major pharma deal with GSK plc. Worth up to $650 million and possibly more if an option is exercised, the multitarget alliance aims to discover and develop novel treatments for Parkinson’s disease and another neurodegenerative indication. Nearly $3.8 ...
GSK announces positive topline results of Phase lll study of …
GlaxoSmithKline (GSK) today announced positive, top-line results of the ADVANCE-Parkinson’s Disease (PD) Phase III clinical study, conducted by Impax Pharmaceuticals, of IPX066 versus immediate-release (IR) carbidopa-levodopa (CD-LD) in …
GSK and Impax announce positive topline results of ASCEND …
GlaxoSmithKline (GSK) and Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. (NASDAQ: IPXL) today announced top-line results of the ASCEND-PD Phase III clinical study of IPX066 versus carbidopa-levodopa plus entacapone (CLE), in patients with advanced Parkinson’s disease (PD).
- Some results have been removed